发现XZ338，一种高效的BCL-XL降解剂

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-04-15 DOI:10.1016/j.ejmech.2025.117624

Xuan Zhang , Dinesh Thummuri , Wanyi Hu , Xingui Liu , Peiyi Zhang , Shuo Zhou , Daohong Zhou , Guangrong Zheng

{"title":"发现XZ338，一种高效的BCL-XL降解剂","authors":"Xuan Zhang , Dinesh Thummuri , Wanyi Hu , Xingui Liu , Peiyi Zhang , Shuo Zhou , Daohong Zhou , Guangrong Zheng","doi":"10.1016/j.ejmech.2025.117624","DOIUrl":null,"url":null,"abstract":"<div><div>BCL-X<sub>L</sub> is a crucial anti-apoptotic protein involved in tumorigenesis and resistance to cancer chemotherapy. Transitioning from conventional inhibitors to PROTAC degraders has shown promising potential, particularly in minimizing the on-target thrombocytopenia linked to BCL-X<sub>L</sub> inhibition. However, reported BCL-X<sub>L</sub> degraders were mostly derived from BCL-X<sub>L</sub>/BCL-2 dual inhibitor ABT-263, which also inhibits or degrades BCL-2 and can potentially cause neutropenia when combined with conventional chemotherapy as seen with ABT-263 in the clinic. The goal of the present study is to develop a highly specific BCL-X<sub>L</sub> degrader without BCL-2 inhibition/degradation. In this study, XZ338, a highly potent and selective BCL-X<sub>L</sub> degrader derived from BCL-X<sub>L</sub> specific inhibitor A-1331852, was generated. XZ338 is 70-fold more potent than ABT-263 against MOLT-4 T-ALL cells, with over 89-fold selectivity for MOLT-4 cells over human platelets.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"291 ","pages":"Article 117624"},"PeriodicalIF":6.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of XZ338, a highly potent BCL-XL degrader\",\"authors\":\"Xuan Zhang , Dinesh Thummuri , Wanyi Hu , Xingui Liu , Peiyi Zhang , Shuo Zhou , Daohong Zhou , Guangrong Zheng\",\"doi\":\"10.1016/j.ejmech.2025.117624\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>BCL-X<sub>L</sub> is a crucial anti-apoptotic protein involved in tumorigenesis and resistance to cancer chemotherapy. Transitioning from conventional inhibitors to PROTAC degraders has shown promising potential, particularly in minimizing the on-target thrombocytopenia linked to BCL-X<sub>L</sub> inhibition. However, reported BCL-X<sub>L</sub> degraders were mostly derived from BCL-X<sub>L</sub>/BCL-2 dual inhibitor ABT-263, which also inhibits or degrades BCL-2 and can potentially cause neutropenia when combined with conventional chemotherapy as seen with ABT-263 in the clinic. The goal of the present study is to develop a highly specific BCL-X<sub>L</sub> degrader without BCL-2 inhibition/degradation. In this study, XZ338, a highly potent and selective BCL-X<sub>L</sub> degrader derived from BCL-X<sub>L</sub> specific inhibitor A-1331852, was generated. XZ338 is 70-fold more potent than ABT-263 against MOLT-4 T-ALL cells, with over 89-fold selectivity for MOLT-4 cells over human platelets.</div></div>\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":\"291 \",\"pages\":\"Article 117624\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0223523425003897\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425003897","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

BCL-XL是一种重要的抗凋亡蛋白，参与肿瘤发生和对癌症化疗的耐药性。从传统抑制剂到PROTAC降解剂的过渡显示出很好的潜力，特别是在最小化与BCL-XL抑制相关的靶血小板减少方面。然而，报道的BCL-XL降降剂大多来自BCL-XL/BCL-2双抑制剂ABT-263， ABT-263也抑制或降解BCL-2，并且在与常规化疗联合使用时可能导致中性粒细胞减少，如ABT-263在临床上所见。本研究的目标是开发一种高度特异性的无BCL-2抑制/降解的BCL-XL降解剂。在本研究中，从BCL-XL特异性抑制剂a -1331852衍生出高效、选择性的BCL-XL降解剂XZ338。XZ338对MOLT-4 T-ALL细胞的效力是ABT-263的70倍，对MOLT-4细胞对人血小板的选择性超过89倍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Discovery of XZ338, a highly potent BCL-XL degrader

查看原文本刊更多论文

Discovery of XZ338, a highly potent BCL-XL degrader

BCL-X_L is a crucial anti-apoptotic protein involved in tumorigenesis and resistance to cancer chemotherapy. Transitioning from conventional inhibitors to PROTAC degraders has shown promising potential, particularly in minimizing the on-target thrombocytopenia linked to BCL-X_L inhibition. However, reported BCL-X_L degraders were mostly derived from BCL-X_L/BCL-2 dual inhibitor ABT-263, which also inhibits or degrades BCL-2 and can potentially cause neutropenia when combined with conventional chemotherapy as seen with ABT-263 in the clinic. The goal of the present study is to develop a highly specific BCL-X_L degrader without BCL-2 inhibition/degradation. In this study, XZ338, a highly potent and selective BCL-X_L degrader derived from BCL-X_L specific inhibitor A-1331852, was generated. XZ338 is 70-fold more potent than ABT-263 against MOLT-4 T-ALL cells, with over 89-fold selectivity for MOLT-4 cells over human platelets.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.